Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 961 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Solid Tumors, Tumors
Interventions
Arm 1- Dose Escalation, Arm 1- Dose Expansion
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more
Conditions
Prostatic Neoplasms, Prostatic Cancer
Interventions
ETBX-071; adenoviral PSA vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-051; adenoviral brachyury vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Results available

Decitabine and Talazoparib in Untreated AML and R/R AML

NCT02878785
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, talazoparib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Tumors, Unknown Primary Tumors, Adenocarcinoma
Interventions
Capecitabine, Carboplatin, Paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer, Ampullary Cancer
Interventions
FOX dose-escalation algorithm
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Pertuzumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions
INZ-701, Control Arm (Conventional Therapy)
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
1 Year to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Fort Worth, Texas
Conditions
Myeloma, Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Cancer
Interventions
AB801, Docetaxel
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Conditions
Advanced Solid Tumors
Interventions
Debio 0123
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Grand Rapids, Michigan • New York, New York • San Antonio, Texas + 1 more
Conditions
Erectile Dysfunction
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Beverly Hills, California + 26 more
Conditions
Advanced/Metastatic Solid Tumors
Interventions
ADG126 Mono, ADG126-anti PD1, ADG126-ADG106
Biological
Lead sponsor
Adagene Inc
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Conditions
Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Rebastinib, Paclitaxel, Eribulin Mesylate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
COVID-19 Infection
Interventions
Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Drug · Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Claremont, California • Duarte, California • Thousand Oaks, California
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Partial Oncolysis, SV-102
Procedure · Drug
Lead sponsor
Syncromune, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 19 more
Conditions
Alport Syndrome
Interventions
Vonafexor
Drug
Lead sponsor
Enyo Pharma
Industry
Eligibility
16 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Boise, Idaho + 4 more
Conditions
Pompe Disease (Late-onset), Pompe Disease Late-Onset, LOPD
Interventions
AB-1009 (GAA Gene)
Genetic
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Phoenix, Arizona • Irvine, California • Palo Alto, California + 6 more
Conditions
Hematological Malignancy
Interventions
Isatuximab SAR650984, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more
Conditions
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 5 more
Conditions
Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Conditions
Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan), Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
28
States / cities
San Diego, California • Torrance, California • Denver, Colorado + 19 more
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Conditions
Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
iPSC-CL
Biological
Lead sponsor
HeartWorks, Inc.
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota